News · 26 weeks121-7%
2026-04-052026-09-27
Mix5490d
- Insider34(63%)
- Other11(20%)
- SEC Filings5(9%)
- Earnings2(4%)
- Analyst2(4%)
Latest news
25 items- INSIDERDirector Mignone Roberto converted options into 264 shares, increasing direct ownership by 3% to 10,274 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 5% to 5,020 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Technology Officer Chudova Darya sold $1,377,364 worth of shares (7,738 units at $178.00), decreasing direct ownership by 10% to 70,635 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Azar Alex M Ii sold $144,550 worth of shares (826 units at $175.00), decreasing direct ownership by 50% to 825 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Krognes Steve E. sold $1,172,886 worth of shares (6,674 units at $175.74), decreasing direct ownership by 46% to 7,906 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Tariq Musa converted options into 249 shares and sold $20,300 worth of shares (116 units at $175.00), increasing direct ownership by 1% to 11,449 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- SECSEC Form 144 filed by Guardant Health Inc.144 - Guardant Health, Inc. (0001576280) (Subject)
- INSIDERDirector Azar Alex M Ii converted options into 1,651 shares (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Information Officer Kalia Kumud sold $632,193 worth of shares (4,000 units at $158.05), decreasing direct ownership by 9% to 39,794 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- PRGuardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer ScreeningSecond largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholders Milestone marks rapid adoption by insurers for the most clinically-validated blood test for CRC Increasing total covered Shield lives ages 45 and older to approximately 94 million, representing the overwhelming majority of eligible patients in the U.S. Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per ACS guidelines. Evi
- PRGuardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung CancerResearch highlights the significance of genomic and epigenomic profiling approaches to characterize lung tumors, identify biomarkers, and support risk stratification Real-world studies examine the complementary roles of plasma- and tissue-based testing, including data from Asia and the Middle East Educational symposium and expert panel discussion to provide insights on the expanding role of plasma-based ctDNA throughout the patient journey Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstracts—including one mini oral presentation—showcasing advances in methylation-based tumo
- ANALYSTUBS resumed coverage on Guardant Health with a new price targetUBS resumed coverage of Guardant Health with a rating of Buy and set a new price target of $225.00
- PRBusiness Insider Names Guardant Health One of America's Most Innovative BusinessesEarning the highest five-star recognition alongside only 12 other companies in the biotechnology category Recognition underscores Guardant’s leadership in precision oncology including patient growth and years of sustained R&D investment Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it has been named to Business Insider’s America's Most Innovative Businesses 2027 list, earning the highest rating available with a five-star recognition awarded to only other 12 biotechnology research companies in the category. The inaugural Business Insider list recognizes companies for their innovative performance over the preceding five years, positioning Gu
- ANALYSTRothschild & Co Redburn initiated coverage on Guardant Health with a new price targetRothschild & Co Redburn initiated coverage of Guardant Health with a rating of Buy and set a new price target of $203.00
- PRGuardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast CancerApproval recommends repeat Guardant360 CDx testing every three months during therapy to detect emerging ESR1 mutations before clinical or radiographic disease progressionIn the Phase III SERENA-6 trial, ctDNA-guided treatment using Guardant360 CDx with camizestrant plus a CDK4/6 inhibitor following detection of an ESR1 mutation reduced the risk of disease progression or death by 56%Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer harbor
- PRGuardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer ScreeningLargest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholders Increasing total covered Shield lives ages 45 and older to approximately 90 million, representing the vast majority of eligible patients in the U.S. Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in Carelon Healthcare Services clinical guidelines effective November 15. Carelon Healthcare Services is one of the largest specialty benefits managers in the country and subsidiary of one of the largest heal
- INSIDERCo-Chief Executive Officer Eltoukhy Helmy disposed of 25,000 shares, acquired 25,000 shares and gifted 30,000 shares (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERCo-Chief Executive Officer Talasaz Amirali sold $6,343,384 worth of shares (37,500 units at $169.16) (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Mignone Roberto converted options into 264 shares, increasing direct ownership by 3% to 10,010 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- PRGuardant Health to Appeal Federal District Court JudgmentCurrent Guardant Reveal, Shield products excluded from final District Court order Company has validated Guardant360 design improvements to exclude impact of potential royalties Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. "We strongly disagree with this decision and will promptly be appealing for its overturn," said John Saia,
- PRTwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the University of Washington More Than $245.2 Million in Damages, Accrued Royalties and InterestCourt preserves 2023 willful infringement verdict and orders a 6% royalty on sales of 11 Guardant Health products and services found to infringe two patents underlying TwinStrand Duplex Sequencing® technology Court enters judgment in favor of TwinStrand and the University of Washington on validity of the asserted claims of both patents TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. District Court for the District of Delaware entered final judgment on Aug. 21, 2026, in favor of TwinStrand and the University of Washington (UW) in their patent infringement suit against Guardant Health, Inc. (NASDAQ:GH). The final judgment pr
- INSIDERDirector Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 5% to 4,788 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Tariq Musa converted options into 250 shares and sold $18,148 worth of shares (116 units at $156.45), increasing direct ownership by 1% to 11,316 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief People Officer Monroe Terilyn J. exercised 46,300 shares at a strike of $22.70 and sold $7,645,218 worth of shares (46,300 units at $165.12) (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERCo-Chief Executive Officer Eltoukhy Helmy gifted 35,000 shares and received a gift of 35,000 shares (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
GH FAQ
7 questionsWhat does Guardant Health Inc. do?
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic...Where does GH stock trade?
Guardant Health Inc. (GH) is listed on NASDAQ.What sector and industry is GH in?
Guardant Health Inc. operates in the Health Care sector, Medical Specialities industry.When did Guardant Health Inc. go public?
Guardant Health Inc. (GH) completed its IPO in 2018.What are analysts saying about GH?
Guardant Health Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-09-09.What companies are similar to GH?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare GH side-by-side with any of them on Quantisnow.How can I track GH on Quantisnow?
Quantisnow aggregates Guardant Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GH to receive live email and push alerts on every new disclosure.